Overview

Placebo-controlled, Proof-of-concept Study to Evaluate the Safety and Efficacy of Lanifibranor Alone and in Combination With SGLT2 Inhibitor EmpaGliflozin in patiEnts With NASH and Type 2 Diabetes Mellitus

Status:
Not yet recruiting

Trial end date:
2023-07-01

Target enrollment:

Participant gender:

Summary

The study in the T2DM population is intended to confirm the lanifibranor effect versus placebo on glycemic control and confirm a positive effect of the combination of lanifibranor with an SGLT2 inhibitor on glycemic control.

Phase:

Phase 2

Details

Lead Sponsor:

Inventiva Pharma

Treatments:

Empagliflozin